The safety outcomes in diabetic patient groups mirrored the expected gastrointestinal class effects seen in non-diabetic populations [2]
The following table presents the subcutaneous dosing regimens of approved GLP-1 and GLP-1/GIP agonists: * Filed for obesity and overweight with the FDA in 2022 [3] Originally, semaglutide was approved for the treatment of diabetes mellitus type 2 [4]
The bill would require MassHealth to cover FDA-approved anti-obesity medications (including Wegovy, Saxenda, and Zepbound) for any enrollee with: BMI 30, or BMI 27 with at least one weight-related comorbidity The bill includes a fiscal note estimating first-year cost of $680 million, assuming 6% uptake among eligible enrollees
Choose the site with healthier skin
ODonnellJFinerNNRichWBarshopBABarringtonKJ
However, it isnt necessarily something that everyone needs, at least in the same capacity